Stockreport

Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)

Catalyst Pharmaceuticals, Inc.  (CPRX) 
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.catalystpharma.com
PDF CMS-001 trial is the first and only double-blinded, placebo-controlled study ever conducted in genetically confirmed CMS patients Results in full population across al [Read more]